We observed that, after anti-Thy1 antibody treatment in the DMBA+Ab group, the number of large tumors, tumor incidence, and lymphocyte infiltration were significantly reduced compared to the DMBA group, indicating that inhibiting ILCs limited tumor expansion and tumor burden. Here, THY1 is linked to neoplasm.